ANIK — ANIKA THERAPEUTICS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
ANIK FAQ
What is ANIK's P/E ratio?
ANIKA THERAPEUTICS INC (ANIK) currently trades at a P/E ratio of 673.94.
What is ANIK's ROE?
ANIKA THERAPEUTICS INC reports a Return on Equity (ROE) of -8.26%.
What is ANIK's dividend yield?
ANIKA THERAPEUTICS INC offers a dividend yield of 0.00%.
What is ANIK's Deepscope Quality Score?
Deepscope rates ANIK's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ANIK?
Deepscope's AI Timing Score for ANIK is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ANIK belong to?
ANIKA THERAPEUTICS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 14.48
Price
0.12
(0.83%)
Day Change
|
|
|---|
ANIK มีคุณภาพโดยรวมยังไม่ดีนัก ( คะแนนปัจจัยพื้นฐาน = 54) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio ค่อนข้างสูง
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำเมื่อเทียบกับอัตราผลตอบแทนผู้ถือหุ้น(ROE)
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ยังไม่ดีนัก , ...
| ปัจจัยทางคุณภาพ |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 14.48 |
| PBV / Sector |
1.47 / 2.76
GOOD
|
| Earning Per Share | -0.81 |
| PE / Sector |
673.94 / 23.64
|
| PEG or PE/Growth / Sector |
5.94 / 0.13
|
| Average 1M Daily Value |
1.00 M
GREAT
|
| Average 1W Daily Value |
0.77 M
GREAT
|
| ปัจจัยทางเทคนิค |
|
28% |
| สุขภาพทางการเงิน |
|
45% |
| ประสิทธิภาพการทำกำไร |
|
56% |
| ผลตอบแทนต่อผู้ถือหุ้น |
|
4% |
| รายละเอียดการจดทะเบียน |
| Analyze Date | 2026-06-06 09:08:26 |
| Symbol | ANIK |
| Name | ANIKA THERAPEUTICS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 13.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 196.79 / 9,835.56 |
| ข่าว, ประมาณการ, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730
Phone: 781 457 9000
Website: https://www.anika.com
Employees: 235
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google